Liliana Nordbakk started her career in software rather than biology, and she describes the genome as code that can be read, tested, and programmed, an approach shaped by co-founding NorCom in 1986, leading it through a Frankfurt IPO, and later co-founding the biotech company Kamau Therapeutics. She has been part of Silicon Valley's angel investing scene since 2003, chaired the life sciences group at Band of Angels for over thirteen years, focuses on startups that combine genome engineering with machine learning, and now leads global life sciences investing for Neva from San Francisco, drawing on an earlier background in accounting and investor communications and past experience connecting German and American tech companies through her firm Motke Capital.
About their Fund
Neva SGR
Neva SGR is a venture capital fund backed by Intesa Sanpaolo that connects Italian entrepreneurs to global investors and helps international founders enter Italy's industrial and scientific network, drawing on the bank's connections to help portfolio companies with customer introductions, coaching, governance, fundraising, and debt access, while also running a separate fund that invests in the infrastructure of the startup ecosystem itself and a Lombardy-focused fund for cleantech companies with proven technology. It focuses on companies already generating at least €5M in revenue in fields like life sciences, energy, digital transformation, and aerospace, has built a portfolio spanning areas such as fusion energy, quantum computing, and biotech, and offers access to its funds to both institutional investors and, through Fideuram and Intesa Sanpaolo Private Banking, private banking clients.
Notable Fund
Investments
Sheets they're in
Sheets they're Fund is in
Popular Investors
.svg)
.jpeg){kind=logo}
.jpeg){kind=logo}
.png)
.jpeg)
.jpeg)
.jpeg)